Page 5 - Pharma Sctors
Lupin likely to demerge its active pharmaceutical ingredients business
As such the API business contributes around 7 percent to Lupin's overall turnover
 "Lupin likely to demerge its active pharmaceutical ingredients business")
Self-regulatory body for pharma industry on cards: Mansukh Mandaviya
Mandaviya says joint squads of state and Centre formed for risk-based assessment of plants
 "Self-regulatory body for pharma industry on cards: Mansukh Mandaviya")
Fewer Indian pharma plants get US FDA action notice in 2023, so far
6 per cent of inspections in first 6 months of CY23 resulted in OAI status
 "Fewer Indian pharma plants get US FDA action notice in 2023, so far")
Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD
Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services
 "Lupin signs MoU with Maharashtra govt to combat rising prevalence of CVD")
Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data
Focus on profitability, and less options other reasons behind the slowdown seen till May this year
 "Regulatory woes torpedo PE/VC deals in e-pharma sector, shows data")
USFDA inspections of Indian sites still below pre-Covid-19 levels
On an average Indian sites have had only a 9% share of total global inspections, analysts point out
 "USFDA inspections of Indian sites still below pre-Covid-19 levels")
India's contribution to global clinical trials at 4% during 2010-22: Study
Trials sponsored by top 20 pharma companies increased 10% since 2013
 "India's contribution to global clinical trials at 4% during 2010-22: Study")
Online pharmacies suffer without regulatory prescriptions in India
The absence of a legal framework governing this fast-growing segment of the pharma retailing business is causing confusion in the industry
 "Online pharmacies suffer without regulatory prescriptions in India")
Indian pharma R&D spends stay stagnant three years after pandemic downturn
Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US
 "Indian pharma R&D spends stay stagnant three years after pandemic downturn")
Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins
Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady
 "Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins")
Pharma firms with India focus preferred as US market concerns grow
Steady outlook and higher returns triggers for companies refining their strategy
 "Pharma firms with India focus preferred as US market concerns grow")
BDR Pharma prostate cancer drug at 1/3rd of innovator brand price
The price for a bottle of 60 tablets is Rs 22,500 and for a bottle of 120 tablets is Rs 45,000
 "BDR Pharma prostate cancer drug at 1/3rd of innovator brand price")
Drug regulator halts production at Maiden Pharma's Sonipat unit
Centre forms panel to analyse causal relation between deaths and cough syrups
 "Drug regulator halts production at Maiden Pharma's Sonipat unit")
Cash is king! Investing strategies to ride out choppy markets
They turn cautious and prefer defensive bets
 "Cash is king! Investing strategies to ride out choppy markets")
Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more
From World Bank slashing India's economic growth to Maiden Pharma's cough syrup issue, here are the top headlines on Friday morning
 "Top headlines: Growth forecast, Maiden Pharma cough syrup issue, and more")
Udaan starts multiple deliveries per day for pharmacies in six cities
Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...
 "Udaan starts multiple deliveries per day for pharmacies in six cities")
Land parcels of pharma PSUs find no takers, but momentum likely in few mths
In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process
 "Land parcels of pharma PSUs find no takers, but momentum likely in few mths")
Deja vu? Key reasons why Jefferies thinks the market rally may not sustain
The information technology sector (IT), Jefferies believes, remains at significant risk of sell-off if the Nifty were to correct
 "Deja vu? Key reasons why Jefferies thinks the market rally may not sustain")
Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore
Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent
 "Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore")
Metropolis tanks 27% in 1-mth on promoter stake sale buzz, latter clarifies
The promoters of Metropolis Healthcare on Monday after market hours clarified that they have no intention to exit the business.
 "Metropolis tanks 27% in 1-mth on promoter stake sale buzz, latter clarifies")
